TY - JOUR
T1 - Dose escalation by image-guided intensity-modulated radiotherapy leads to an increase in pain relief for spinal metastases
T2 - A comparison study with a regimen of 30 Gy in 10 fractions
AU - He, Jinlan
AU - Xiao, Jianghong
AU - Peng, Xingchen
AU - Duan, Baofeng
AU - Li, Yan
AU - Ai, Ping
AU - Yao, Min
AU - Chen, Nianyong
N1 - Publisher Copyright:
© He et al.
PY - 2017
Y1 - 2017
N2 - Purpose: Under the existing condition that the optimum radiotherapy regimen for spinal metastases is controversial, this study investigates the benefits of dose escalation by image-guided intensity-modulated radiotherapy (IG-IMRT) with 60-66 Gy in 20-30 fractions for spinal metastases. Results: In the dose-escalation group, each D50 of planning gross tumor volume (PGTV) was above 60 Gy and each Dmax of spinal cord planning organ at risk volume (PRV) was below 48 Gy. The median biological effective dose (BED) of Dmax of spinal cord was lower in the dose-escalation group compared with that in the 30- Gy group (69.70 Gy vs. 83.16 Gy, p < 0.001). After one month and three months of the radiotherapy, pain responses were better in the dose-escalation group than those in the 30-Gy group (p = 0.005 and p = 0.024), and the complete pain relief rates were respectively 73.69% and 34.29% (p = 0.006), 73.69% and 41.38% (p = 0.028) in two compared groups. In the dose-escalation group, there is a trend of a longer duration of pain relief, a longer overall survival and a lower incidence of acute radiation toxicities. No late radiation toxicities were observed in both groups. Materials and Methods: Dosimetric parameters and clinical outcomes, including pain response, duration of pain relief, radiation toxicities and overall survival, were compared among twenty-five metastatic spinal lesions irradiated with the doseescalation regimen and among forty-four lesions treated with the 30-Gy regimen. Conclusions: Conventionally-fractionated IG-IMRT for spinal metastases could escalate dose to the vertebral lesions while sparing the spinal cord, achieving a better pain relief without increasing radiation complications.
AB - Purpose: Under the existing condition that the optimum radiotherapy regimen for spinal metastases is controversial, this study investigates the benefits of dose escalation by image-guided intensity-modulated radiotherapy (IG-IMRT) with 60-66 Gy in 20-30 fractions for spinal metastases. Results: In the dose-escalation group, each D50 of planning gross tumor volume (PGTV) was above 60 Gy and each Dmax of spinal cord planning organ at risk volume (PRV) was below 48 Gy. The median biological effective dose (BED) of Dmax of spinal cord was lower in the dose-escalation group compared with that in the 30- Gy group (69.70 Gy vs. 83.16 Gy, p < 0.001). After one month and three months of the radiotherapy, pain responses were better in the dose-escalation group than those in the 30-Gy group (p = 0.005 and p = 0.024), and the complete pain relief rates were respectively 73.69% and 34.29% (p = 0.006), 73.69% and 41.38% (p = 0.028) in two compared groups. In the dose-escalation group, there is a trend of a longer duration of pain relief, a longer overall survival and a lower incidence of acute radiation toxicities. No late radiation toxicities were observed in both groups. Materials and Methods: Dosimetric parameters and clinical outcomes, including pain response, duration of pain relief, radiation toxicities and overall survival, were compared among twenty-five metastatic spinal lesions irradiated with the doseescalation regimen and among forty-four lesions treated with the 30-Gy regimen. Conclusions: Conventionally-fractionated IG-IMRT for spinal metastases could escalate dose to the vertebral lesions while sparing the spinal cord, achieving a better pain relief without increasing radiation complications.
UR - http://www.scopus.com/inward/record.url?scp=85038819672&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85038819672&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.18979
DO - 10.18632/oncotarget.18979
M3 - Article
C2 - 29348828
AN - SCOPUS:85038819672
SN - 1949-2553
VL - 8
SP - 112330
EP - 112340
JO - Oncotarget
JF - Oncotarget
IS - 68
ER -